Grady Burnett - Kaleido Biosciences Director

KLDODelisted Stock  USD 0.01  0.00  0.00%   

Director

Mr. Grady Burnett is Director of the Company. Mr. Burnett is CoFounder and General Partner at Bow Capital, an early stage VC firm he started in July 2016. Previously, he served as Chief Operating Officer of Flurry, Inc., a mobile analytics, monetization and advertising company. Mr. Burnett previously served as Vice President, Global Sales and Operations at Facebook, Inc., Director, North American Sales and Operations for Google, and Vice President, North American Sales, at DoubleClick. He serves on the Boards of East Palo Alto Tennis and Tutoring and Menlo School since 2018.
Tenure 6 years
Professional MarksMBA
Phone617 674 9000
Webhttps://kaleido.com
Burnett is a graduate of the University of Michigan and received his M.B.A. from Harvard Business School.

Kaleido Biosciences Management Efficiency

The company has return on total asset (ROA) of (0.9993) % which means that it has lost $0.9993 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.8057) %, meaning that it created substantial loss on money invested by shareholders. Kaleido Biosciences' management efficiency ratios could be used to measure how well Kaleido Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 5.55 M in liabilities with Debt to Equity (D/E) ratio of 2.05, implying the company greatly relies on financing operations through barrowing. Kaleido Biosciences has a current ratio of 1.39, which is within standard range for the sector. Debt can assist Kaleido Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Kaleido Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Kaleido Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Kaleido to invest in growth at high rates of return. When we think about Kaleido Biosciences' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Kristina CashmanBassett Furniture Industries
51
Frank McGaugheyHaverty Furniture Companies
63
Vicki PalmerHaverty Furniture Companies
67
George HendersonBassett Furniture Industries
69
Duncan GageLGI Homes
68
William WardenBassett Furniture Industries
65
John BelkBassett Furniture Industries
58
John GloverHaverty Furniture Companies
73
John AlschulerSL Green Realty
72
Frederick SchuermannHaverty Furniture Companies
72
Barre SeibertTootsie Roll Industries
79
Arthur SchaierHanover Foods
66
Jennifer CarterHanover Foods
44
Allison DukesHaverty Furniture Companies
43
John LevySL Green Realty
84
Peter BrownBassett Furniture Industries
72
Walter McDowellBassett Furniture Industries
63
Thomas HoughHaverty Furniture Companies
63
Lana LewisBrentTootsie Roll Industries
74
G HoughHaverty Furniture Companies
66
Edward LippyHanover Foods
78
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts. Kaleido Biosciences operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 76 people. Kaleido Biosciences [KLDO] is a Pink Sheet which is traded between brokers as part of OTC trading. Kaleido Biosciences is listed under Pharmaceutical Products category by Fama And French industry classification.

Management Performance

Kaleido Biosciences Leadership Team

Elected by the shareholders, the Kaleido Biosciences' board of directors comprises two types of representatives: Kaleido Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kaleido. The board's role is to monitor Kaleido Biosciences' management team and ensure that shareholders' interests are well served. Kaleido Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kaleido Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
Geoffrey Maltzahn, President Co-Founder
Jeremy Buzzard, Senior Vice President - Corporate Development
Johannes Vlieg, Chief Scientific Officer
Grady Burnett, Director
Mark Wingertzahn, VP Devel
Bonnie Bassler, Director
Jeffery Moore, Senior Vice President - Finance & Administration
Clare Fisher, Chief Business Officer
LLM JD, Chief Advisor
Jerald Korn, General Counsel, Corporate Secretary
Mike Bonney, Chairman of the Board, CEO
John Sculley, Director
Ruth ThieroffEkerdt, Chief Medical Officer
Theo MelasKyriazi, Independent Director
Kimberly Hocknell, VP Operations

Kaleido Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Kaleido Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.
Note that the Kaleido Biosciences information on this page should be used as a complementary analysis to other Kaleido Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Other Consideration for investing in Kaleido Pink Sheet

If you are still planning to invest in Kaleido Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kaleido Biosciences' history and understand the potential risks before investing.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments